135 related articles for article (PubMed ID: 22337647)
21. Boolean modeling identifies Greatwall/MASTL as an important regulator in the AURKA network of neuroblastoma.
Dahlhaus M; Burkovski A; Hertwig F; Mussel C; Volland R; Fischer M; Debatin KM; Kestler HA; Beltinger C
Cancer Lett; 2016 Feb; 371(1):79-89. PubMed ID: 26616283
[TBL] [Abstract][Full Text] [Related]
22. Microarray data analysis of neuroblastoma: Expression of SOX2 downregulates the expression of MYCN.
Bao J; Qin L; Cui L; Wang X; Meng Q; Zhu L; Zhang S
Mol Med Rep; 2015 Nov; 12(5):6867-72. PubMed ID: 26398570
[TBL] [Abstract][Full Text] [Related]
23. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
[TBL] [Abstract][Full Text] [Related]
24. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma.
Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A
Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189
[TBL] [Abstract][Full Text] [Related]
25. Expression profiling of favorable and unfavorable neuroblastomas.
Hiyama E; Hiyama K; Yamaoka H; Sueda T; Reynolds CP; Yokoyama T
Pediatr Surg Int; 2004 Jan; 20(1):33-8. PubMed ID: 14691637
[TBL] [Abstract][Full Text] [Related]
26. Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression.
Mosse YP; Diskin SJ; Wasserman N; Rinaldi K; Attiyeh EF; Cole K; Jagannathan J; Bhambhani K; Winter C; Maris JM
Genes Chromosomes Cancer; 2007 Oct; 46(10):936-49. PubMed ID: 17647283
[TBL] [Abstract][Full Text] [Related]
27. High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma.
Stallings RL; Nair P; Maris JM; Catchpoole D; McDermott M; O'Meara A; Breatnach F
Cancer Res; 2006 Apr; 66(7):3673-80. PubMed ID: 16585193
[TBL] [Abstract][Full Text] [Related]
28. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
[TBL] [Abstract][Full Text] [Related]
29. Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma.
Alaminos M; Davalos V; Cheung NK; Gerald WL; Esteller M
J Natl Cancer Inst; 2004 Aug; 96(16):1208-19. PubMed ID: 15316056
[TBL] [Abstract][Full Text] [Related]
30. Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma.
Fulda S; Poremba C; Berwanger B; Häcker S; Eilers M; Christiansen H; Hero B; Debatin KM
Cancer Res; 2006 Oct; 66(20):10016-23. PubMed ID: 17047064
[TBL] [Abstract][Full Text] [Related]
31. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
[TBL] [Abstract][Full Text] [Related]
32. How does MYCN amplification make neuroblastomas behave aggressively? Still more questions than answers.
Maris JM
Pediatr Blood Cancer; 2005 Dec; 45(7):869-70. PubMed ID: 16206200
[No Abstract] [Full Text] [Related]
33. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
[TBL] [Abstract][Full Text] [Related]
34. Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastases.
Cobrinik D; Ostrovnaya I; Hassimi M; Tickoo SK; Cheung IY; Cheung NK
Genes Chromosomes Cancer; 2013 Dec; 52(12):1150-66. PubMed ID: 24123354
[TBL] [Abstract][Full Text] [Related]
35. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD
Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465
[TBL] [Abstract][Full Text] [Related]
36. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers.
Prochazka P; Hrabeta J; Vicha A; Cipro S; Stejskalova E; Musil Z; Vodicka P; Eckschlager T
Oncol Rep; 2013 Jun; 29(6):2415-21. PubMed ID: 23563570
[TBL] [Abstract][Full Text] [Related]
37. Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings.
Decock A; Ongenaert M; Vandesompele J; Speleman F
Epigenetics; 2011 Aug; 6(8):962-70. PubMed ID: 21725203
[TBL] [Abstract][Full Text] [Related]
38. High genomic instability predicts survival in metastatic high-risk neuroblastoma.
Stigliani S; Coco S; Moretti S; Oberthuer A; Fischer M; Theissen J; Gallo F; Garavent A; Berthold F; Bonassi S; Tonini GP; Scaruffi P
Neoplasia; 2012 Sep; 14(9):823-32. PubMed ID: 23019414
[TBL] [Abstract][Full Text] [Related]
39. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
[TBL] [Abstract][Full Text] [Related]
40. Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN.
Koppen A; Ait-Aissa R; Koster J; Øra I; Bras J; van Sluis PG; Caron H; Versteeg R; Valentijn LJ
Int J Cancer; 2008 Apr; 122(7):1455-64. PubMed ID: 18059033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]